EID Parry (India) Ltd
EID Parry is engaged in Sugar, Nutraceuticals and ethanol production. It also has a significant presence in the Farm Inputs business including Bio pesticides through its subsidiary, Coromandel International Limited. [1]
- Market Cap ₹ 8,750 Cr.
- Current Price ₹ 493
- High / Low ₹ 574 / 377
- Stock P/E 29.6
- Book Value ₹ 156
- Dividend Yield 2.23 %
- ROCE 12.2 %
- ROE 11.1 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Debtor days have improved from 29.66 to 21.30 days.
Cons
- Stock is trading at 3.17 times its book value
- The company has delivered a poor sales growth of 2.11% over past five years.
- Tax rate seems low
- Company has a low return on equity of 8.63% for last 3 years.
- Earnings include an other income of Rs.262.19 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,271 | 1,542 | 1,992 | 1,782 | 2,081 | 2,601 | 2,248 | 1,921 | 1,845 | 1,875 | 2,024 | 2,496 | |
1,248 | 1,438 | 1,759 | 1,683 | 1,863 | 2,540 | 1,903 | 1,754 | 1,876 | 1,780 | 1,854 | 2,280 | |
Operating Profit | 22 | 104 | 233 | 99 | 218 | 61 | 345 | 167 | -31 | 94 | 171 | 216 |
OPM % | 2% | 7% | 12% | 6% | 10% | 2% | 15% | 9% | -2% | 5% | 8% | 9% |
167 | 170 | 373 | 163 | 171 | 97 | 157 | 126 | 372 | 141 | 1,101 | 262 | |
Interest | 48 | 64 | 137 | 196 | 151 | 167 | 140 | 113 | 113 | 136 | 93 | 46 |
Depreciation | 74 | 74 | 108 | 97 | 102 | 112 | 111 | 113 | 114 | 120 | 120 | 120 |
Profit before tax | 67 | 136 | 361 | -31 | 136 | -122 | 252 | 67 | 114 | -20 | 1,058 | 312 |
Tax % | -18% | -1% | 8% | 185% | -9% | 24% | -13% | -50% | -43% | 109% | 18% | 9% |
Net Profit | 79 | 137 | 332 | 27 | 148 | -92 | 284 | 101 | 163 | 2 | 865 | 284 |
EPS in Rs | 4.58 | 7.91 | 18.87 | 1.51 | 8.43 | -5.24 | 16.13 | 5.71 | 9.22 | 0.10 | 48.83 | 15.98 |
Dividend Payout % | 44% | 51% | 32% | 0% | 36% | 0% | 25% | 53% | 33% | 0% | 0% | 69% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 2% |
3 Years: | 11% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 1% |
3 Years: | 34% |
TTM: | 9% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 40% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | |
Reserves | 1,133 | 1,200 | 1,329 | 1,262 | 1,352 | 1,265 | 1,460 | 1,620 | 1,696 | 1,696 | 2,576 | 2,742 |
Borrowings | 654 | 885 | 1,834 | 1,977 | 1,845 | 1,319 | 943 | 1,018 | 832 | 1,090 | 603 | 147 |
278 | 342 | 454 | 573 | 681 | 1,128 | 1,019 | 1,386 | 1,339 | 1,266 | 1,077 | 1,168 | |
Total Liabilities | 2,082 | 2,444 | 3,635 | 3,829 | 3,895 | 3,730 | 3,440 | 4,042 | 3,885 | 4,069 | 4,275 | 4,075 |
783 | 765 | 1,230 | 1,481 | 1,481 | 1,508 | 1,480 | 1,391 | 1,287 | 1,329 | 1,118 | 1,244 | |
CWIP | 32 | 49 | 62 | 49 | 24 | 33 | 8 | 5 | 11 | 19 | 112 | 15 |
Investments | 434 | 683 | 871 | 545 | 683 | 811 | 786 | 878 | 979 | 999 | 1,010 | 1,119 |
833 | 947 | 1,472 | 1,754 | 1,708 | 1,378 | 1,166 | 1,768 | 1,607 | 1,722 | 2,034 | 1,698 | |
Total Assets | 2,082 | 2,444 | 3,635 | 3,829 | 3,895 | 3,730 | 3,440 | 4,042 | 3,885 | 4,069 | 4,275 | 4,075 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-108 | -7 | -93 | 146 | 293 | 945 | 518 | -19 | -4 | -16 | -37 | 439 | |
138 | -83 | -188 | 143 | -1 | -95 | 27 | 45 | 397 | -32 | 645 | 269 | |
-29 | 111 | 261 | -262 | -323 | -808 | -594 | -26 | -393 | 57 | -605 | -690 | |
Net Cash Flow | -0 | 21 | -20 | 27 | -31 | 42 | -48 | -1 | 0 | 10 | 3 | 18 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 37 | 52 | 39 | 51 | 46 | 36 | 34 | 26 | 32 | 32 | 36 | 21 |
Inventory Days | 77 | 90 | 228 | 319 | 285 | 147 | 187 | 316 | 258 | 274 | 252 | 207 |
Days Payable | 39 | 44 | 71 | 91 | 89 | 87 | 72 | 163 | 108 | 125 | 80 | 72 |
Cash Conversion Cycle | 76 | 98 | 197 | 278 | 242 | 96 | 150 | 178 | 182 | 180 | 208 | 157 |
Working Capital Days | 160 | 110 | 177 | 187 | 152 | 17 | 12 | 38 | 21 | 56 | 116 | 39 |
ROCE % | 5% | 10% | 9% | 4% | 9% | 2% | 15% | 10% | 7% | 4% | 14% | 12% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1d
- Investor Call Audio Recording 2d
- Announcement under Regulation 30 (LODR)-Investor Presentation 18 May
- Announcement under Regulation 30 (LODR)-Investor Presentation 17 May
-
Annual General Meeting (AGM) And Book Closure.
17 May - The Register of Members and Share Transfer Books of the Company will be closed from Wednesday, August 3, 2022 to Tuesday, August 9, 2022 (both …
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Transcript - Feb 22
-
Transcript - Nov 21
-
Transcript - Aug 21
-
Transcript - Jun 21
-
Transcript - Jan 21
-
Transcript - Nov 20
-
Transcript - Jun 20
-
Transcript - Jan 20
-
Transcript - Oct 19
-
Transcript - Jul 19
-
Transcript - May 19
-
Transcript - Jan 19
-
Transcript - Nov 18
-
Transcript - Aug 18
-
Transcript - May 18
-
Transcript - Jan 18
-
Transcript - Oct 17
-
Transcript - May 17
-
Transcript - Jan 16
Business Segments
Sugar: The Co has been manufacturing sugar for more than two centuries and has expertise to manufacture sugar to critical specifications addressing specific customized needs.
Nutraceuticals: The Co creates science-based formulations of nutraceuticals supplements, functional foods, general nutrition, functional cosmetic ingredients and pharmaceutical formulations.
Sanitizers: Handkleen & Sterisafe are hand sanitization products introduced by the Co. [1]
Revenue Split (FY21)
Nutrient and allied business : 66%
Sugar: 20%
Crop protection: 11%
Other: 3 % [2]